Human host genetic factors have been suggested to be determinants of the prevalence and clinical forms of Chagas disease. In this regard, IL-17A is believed to control parasitemia and protect against heart disease. In this work, we assessed whether IL17A gene polymorphisms are related to infection and/or development of the cardiac form of Chagas disease by genotyping for five IL17A SNPs (rs4711998, rs8193036, rs3819024, rs2275913 and rs7747909) in 1171 individuals from a Colombian region endemic for Chagas disease, classified as seronegative (n = 595), seropositive asymptomatic (n = 175) and chronic Chagas cardiomyopathy (n = 401). Our results showed that SNP rs8193036, which is located upstream of the coding region of the gene, was slightly associated with protection against T. cruzi infection (P = 0.0170, P FDR = 0.0851, odds ratio (OR) = 0.80, confidence interval (CI) = 0.66-0.96) and associated with protection against the development of cardiomyopathy (P = 0.0065, P FDR = 0.0324, OR = 0.75, CI = 0.60-0.92). This finding suggests that this IL17A polymorphism could be associated with Trypanosoma cruzi infection and the development of chronic cardiomyopathy due to differential expression of cytokine IL-17A.
INTRODUCTION
Chagas disease, which is caused by infection of the protozoan Trypanosoma cruzi, is recognized by the World Health Organization as one of 13 neglected tropical diseases. It is estimated that 65 million people live in endemic regions and that 6 to 8 million are currently infected, with an incidence of 28 000 cases per year. 1 This disease presents two phases: an acute phase and a chronic phase. The chronic phase comes after the acute phase and most patients will remain asymptomatic and will die from a cause other than Chagas disease. However, around 30% of patients will develop one or two symptomatic forms of the disease, namely chronic cardiomyopathy and/or megacolon. 2, 3 Human host genetic factors have been suggested to be determinants of the prevalence and clinical forms of Chagas disease. 4 As such, cytokine and cytokine receptor genes have been studied in order to find any association between genes and the susceptibility and/or development of cardiomyopathy in patients from different endemic countries. 5 Polymorphisms in genes encoding proinflammatory cytokines such as TNF-α, 6, 7 lymphotoxin-α, 8 and IL18 9 have been found to be associated with chronic Chagas cardiomyopathy. Similarly, polymorphisms in genes encoding regulatory cytokines such as IL10, 10 chemokines CCL2, CXCL9 and CXCL10, the chemokine receptor CCR5 11, 12 have also been found to be associated with cardiomyopathy. Our group has studied several polymorphisms in Colombian and Peruvian samples in which we found associations with several cytokine genes, especially IL1B, IL12B, MIF, TGFB and IFNG, and cytokine receptor genes such as CCR2 and CCR5. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Cytokine IL-17A, which is encoded by the IL17A gene located on chromosome 6, is involved in the development of inflammation and host defense against infection by inducing the expression of genes encoding proinflammatory cytokines and chemokines. 23 In Chagas disease, IL-17A has been studied in mouse models and human samples and was shown to control parasitemia levels in mice inoculated with Trypanosoma cruzi and to have an important role in modulating the production of IFN-γ and TNF-α, thereby reducing heart damage. 24 Knockout mice for IL17A gene showed increased parasitemia and died earlier than wild-type mice infected with the parasite. 25 A cross-sectional study conducted in individuals from endemic regions in Brazil showed that chronic Chagas cardiomyopathy patients exhibited lower IL-17A expression than both seronegative individuals and indeterminate asymptomatic patients. 26 Given the importance of IL-17A in controlling T. cruzi infection and protecting against heart tissue damage, we decided to determine whether polymorphisms of the IL17A gene are related to a predisposition to infection and/or development of the cardiac form of Chagas disease.
RESULTS
The five IL17A SNPs for all subjects in this study were in Hardy-Weinberg equilibrium (P40.01). In order to achieve maximum quality in our study, the data were filtered and those individuals who not reach 50% typing for five SNPs were removed from the analysis. The genotyping rate success was over 95% for the different SNPs. By using expectation-maximization algorithm implemented in Haploview 4.2 software, pairwise linkage disequilibrium and haplotypes were estimated. For all cases, r 2 values were minor than 0.8, indicating possible independent effects.
In order to evaluate the association between IL17A gene variant and susceptibility to T. cruzi infection, the allelic and genotypic frequencies of seronegative and seropositive individuals were compared using the χ 2 test or a logistic regression analysis ( Table 1 ). The frequency of allele C in rs8193036 was higher in seronegative than in seropositive individuals, with the difference being statistically significantly (P = 0.0170, odds ratio (OR) = 0.80, CI = 0.66-0.96). However, this significance was lost when applying the Benjamini and Hochberg step up false discovery rate (FDR) correction (P FDR = 0.0851). Similarly, the genotype C/C frequency for rs8193036 was statistically significantly higher in seronegative individuals when applying additive model analysis, although, as above, significance was lost upon application of the Benjamini and Hochberg correction (P = 0.0321, P FDR = 0.1606). For rs2275913, the frequency of allele A was higher in seropositive than in seronegative individuals, with the difference being statistically significantly (P = 0.0453, OR = 1.23, CI = 1.00-1.51). However, as was the case for rs8193036, this significance was lost after applying the Benjamini and Hochberg correction (P FDR = 0.1133). The allelic and genotypic frequencies for rs4711998, rs3189024 and rs7747909 were not statistically significantly different when comparing seropositive and seronegative individuals.
Next, and in order to evaluate the possible association between IL17A genetic variants and chronic Chagas cardiomyopathy, we compared IL17A allelic and genotypic frequencies for seropositive asymptomatic individuals and chronic Chagas cardiomyopathy individuals using the χ 2 test or a logistic regression analysis ( Table 2) . For IL17A rs8193036, the frequency of allele C did not differ significantly when comparing the two groups of individuals.
In contrast, the genotype C/T and T/T frequencies were higher in asymptomatic than in chronic Chagas cardiomyopathy individuals, with these differences being statistically significantly different in the regression model analysis (P = 0.0485, OR = 0.50, CI = 0.25-0.99). However, once again, this significance disappeared upon application of the Benajmini and Hochberg correction (P FDR = 0.2424). The allelic and genotypic frequencies for rs4711998, rs3189024, rs2275913 and rs7747909 were not statistically significantly different when comparing asymptomatic and chronic Chagas cardiomyopathy individuals.
Finally, as our seropositive samples had a proportion of almost three chronic Chagas cardiomyopathy individuals for every asymptomatic subject, we decided to perform an additional analysis by comparing two groups, namely seronegative and chronic Chagas cardiomyopathy individuals ( Table 3 ). In this analysis for IL17A rs8193036, the frequency of allele C was higher in seronegative than in seropositive individuals, with this statistically significant difference remaining after application of the Benajmini and Hochberg correction (P = 0.0065, P FDR = 0.0324, OR = 0.75, CI = 0.60-0.92). Genotype C/C and C/T frequencies were higher in seronegative individuals, with significant differences being found in the additive model analysis after application of the Benajmini and Hochberg correction (P = 0.0070, P FDR = 0.0351 OR = 0.69, CI = 0.52-0.90). Significant differences were also observed in the regression model (P = 0.0124, OR = 0.50, CI = 0.29-0.86) and dominant model analyses (P = 0.0426, OR = 0.76, CI = 0.59-0.99), although in these two models significance was lost when applying the Benajmini and Hochberg correction (P FDR = 0.0618 and P FDR = 0.2129, respectively). For IL17A and rs4711998, the frequency of genotype A/A was lower in chronic Chagas cardiomyopathy individuals than in seronegative individuals, with this difference being statistically significantly in the additive model analysis (P = 0.0389, OR = 0.74, CI = 0.56-0.98). However, significance was lost when applying the Benajmini and Hochberg correction (P FDR = 0.0972). No statistically significantly differences were found for any of the other IL17A gene SNPs analyzed.
DISCUSSION
IL-17A is produced by several cell lines, including Th17 cells, γδ T cells, Natural Killer T cells, NK cells, neutrophils and eosinophils. As this cytokine is produced by innate and adaptive immune system cells, it has been suggested that there may be a bridging function between two immune responses. 27 As IL-17A is a proinflammatory cytokine involved in stimulation of local tissue inflammation, 23 it has been widely studied in the context of infectious diseases. For example, in trypanosomatid protozoa, IL-17A has been shown to be protective against species of the genus Leishmania. Similarly, in a study performed in Sudan with individuals infected with Leishmania donovani, IL-17 was detected in 80% of resistant individuals, whereas IL-17 was detected in only 30% of individuals who had the lethal visceral form of the disease (Kala Azar) prior to the study. Moreover, IL-17 levels have been shown to be predictive of Kala Azar, with individuals who developed this form of the disease in a period of 6 months during the study having significantly lower levels than individuals who remained resistant to the disease throughout the study. 28 Another study in Brazil showed that IL-17 plays a critical role in control of Leishmania infantum infection, with knockout mice for IL-17 receptor A showing an increased parasitemia, increased levels of regulatory cytokine IL-10, smaller inflammatory infiltrates and reduced levels of Ifng, Tbet and iNOS mRNA, thereby suggesting that an increased level of IL-17 response may block IL-10 regulatory environment and contribute to a leishmanicidal effect and parasite clearance. 29 Similar to Leishmania, IL-17 has been shown to be protective against infection and chronic cardiomyopathy development in mice and infected individuals from regions endemic in Trypanosoma cruzi. In mouse models, IL-17A is essential for parasite clearance and protection against cardiac damage, 24,25 and in humans IL-17A levels are directly related to cardiac involvement and infection, being lower in chronic Chagas cardiomyopathy patients than in indeterminate and seronegative patients. 26 Another study showed that IL-17A and IFN-γ adequately stimulate macrophages to engulf T. cruzi parasites, with the authors proposing that a prolonged residence of the parasite in the endosomal/lysosomal compartment is responsible for parasite death due to continuous exposure to lytic machinery. 30 This is similar to the proposal put forward in a study with another protozoan parasite, namely Plasmodium berghei, in mice. In this case, IL-17A was shown to be essential for protection against malaria, with IL-23 inducing macrophages to produce IL-17A and showing an increased survival in wild-type mice compared to knockout mice for IL-23 and IL-17A. IL-17A also stimulates production of the chemokine CCL2/7 and generates a continuous supply of macrophages to the spleen, which might help to efficiently eliminate malaria parasites. 31 Given the evidence that IL-17A contributes to the control and elimination of different protozoan parasite infections, including T. cruzi, we decided to perform an analysis on IL17A gene polymorphisms to look for associations with T. cruzi infection and/ or chronic cardiomyopathy. This is the first work in which IL17A gene polymorphisms are evaluated in individuals from an endemic region of Chagas disease. Our results showed that allele C of rs8193036 was associated with protection against infection by T. cruzi when comparing seronegative and seropositive individuals (OR = 0.80), as well as being associated with protection against Chagas cardiomyopathy when comparing seronegative and cardiac symptomatic individuals (OR = 0.75). In a previous work, rs8193036 was shown to be related to different levels of IL-17A production, with rs8193036 allele C being associated with lower IL17A mRNA expression. 32 In light of these findings, it is clear to us that this polymorphism could be associated with differential IL-17A production in patients. However, as our study population is different to previous populations analyzed, we cannot be certain which exact allele or genotype is related to minor or major IL-17A production. Despite this, our results show that rs8193036 is probably in linkage disequilibrium with some causative variant that affects IL-17A production. Owing to our limited number of asymptomatic patients compared with chronic cardiac symptomatic patients, we believe that our analysis does not show any allelic difference when comparing these two groups of patients, simply an association between rs8193036 and protection against cardiac damage when using the recessive model analysis and before application of the Benjamini and Hochberg FDR correction. However, when comparing chronic Chagas cardiomyopathy and seronegative patients, rs8193036 again showed a significant difference between both groups. In our opinion, this result shows that patients who carry allele C of this SNP are protected against T. cruzi infection, whereas patients who carry allele T are at risk of both becoming infected and of developing heart disease. A possible limitation in this study could be the marked difference of the average age between the different groups of patients (seronegative and chronic Chagas cardiomyopathy); however, we are confident about the consistency of our results, as the statistical significance was still maintained after performing a logistic regression analysis using age as covariate (P = 0.032). Another IL17A SNP, namely rs2275913, has been found to be related to different serum IL-17A levels, with these levels being lower in Chinese patients carrying allele A 33 and higher in Brazilian subjects. 34 Moreover, in an in vitro analysis, rs2275913 was shown to affect levels of IL-17A produced by stimulated T cells and to affect its binding affinity for a critical transcription factor involved in IL-17A regulation. 35 Despite this, our results only showed one significant difference when comparing seropositive and seronegative individuals, although this significance was lost after applying the false discovery rate correction. No differences in allelic and genotypic frequencies of this SNP were found when comparing asymptomatic with chronic Chagas cardiomyopathy individuals or seronegative with chronic Chagas cardiomyopathy individuals.
This study had enough statistical power (~95%) to detect a possible strong association between the analyzed SNPs and the infection by T. cruzi for this endemic population considering an OR = 1.5 (Prevalence = 1.44%); nevertheless, a weaker effect of these genetic variants considering an OR = 1.25 lowers the statistical power (~62%). On the other hand, due to the low number of asymptomatic patients in our set of individuals, our study has a middle high statistical power (~77%) to detect a possible strong association to chronic Chagas cardiomyopathy considering an OR = 1.5 when comparing asymptomatic individuals and chronic Chagas cardiomyopathy patients; however, this power lowers (~30%) considering an OR = 1.25.
In conclusion, we believe that IL17A rs8193036 could be associated with a susceptibility to Chagas disease and the development of chronic cardiomyopathy. This association could be related to different IL-17A production, which enhances parasite clearance from individuals. However, the lack of functional data supporting our results could be considered a limitation of this study. Further studies on this gene with different populations and larger samples sizes, as well as functional analyses, are needed to validate our findings
MATERIALS AND METHODS

Study subjects
For this study, 1171 individuals from an endemic region for Chagas disease in the provinces of Guanentina and Comunera at the department of Santander localized between 5°26′ and 8°08′ north and 72°26′ and 74°32′ west, Colombia, were included. The population in this area of Colombia is a homogeneous mixture, with no specific concentration of any ethnicity. In this zone, symptomatic form of Chagas disease is mainly chronic cardiomyopathy. Samples were collected between 2002 and 2014. These individuals underwent a serological diagnosis for T. cruzi infection by way of enzyme-linked immunosorbent assay and a commercial indirect hemagglutination test. According to the results of these tests, 576 individuals were classified as seropositive for T. cruzi antigens and 595 were classified as seronegative, with this latter group being used as controls. Subsequently, and based on the results of the clinical evaluation, an electrocardiogram and echocardiogram were recorded to detect any conduction alteration and/or structural cardiomyopathy. As a result, 175 seropositive individuals were classified as asymptomatic and 401 individuals were classified as chronic Chagas cardiomyopathy individuals. From this last group, individuals were classified according to severity of cardiomyopathy as follows: CII (n = 166, radiology indicative of light heart hypertrophy or minor ECG alterations), CIII (n = 200, moderate heart hypertrophy and considerable ECG alterations, mainly conduction abnormalities) and CIV (n = 35, severe cardiomegaly and marked ECG alterations, predominantly frequent and/or complex forms of ventricular arrhythmia). All participants were older than 18 years. The mean age of participants was 45.86 years for seronegative individuals, 58.00 for asymptomatic individuals and 63.14 for chronic Chagas cardiomyopathy patients. The sex distribution for the entire group was 55% female and 45% male.
Ethics statement
The Ethics Committees from the Universidad Industrial de Santander and Fundación Cardiovascular de Colombia approved this study in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Written informed consent was obtained from all subjects prior to participation.
Genotyping
Genomic DNA was isolated from 7 ml of an EDTA anticoagulated blood samples using standard salting-out techniques. Five IL17A SNPs (rs4711998, rs8193036, rs3819024, rs22275913 and rs7747909) were selected based on a modified version of a previously reported methodology. 36 Briefly, using Haploview V4.2, 37 SNP selection was performed on the basis of pairwise tagging (r 2 40.80) and minor allele frequencies 40.1, in this case using Colombian-Medellín genotype data from the 1000 genomes project website (http://www.1000genomes.org), 38 covering the IL17A gene and 2 kb upstream. SNPs were genotyped using TaqMan allelic discrimination assays (Applied Biosystems, Foster City, CA, USA) on a LightCycler 480 real-time PCR system (Roche Diagnostics, Basel, Switzerland).
Statistical analysis
The Hardy-Weinberg equilibrium was determined at a significance level of 0.01 for all groups of individuals. In order to find allelic and genotypic associations, we analyzed allelic and genotypic frequencies by comparing seronegative vs seropositive individuals and asymptomatic vs chronic Chagas cardiomyopathy individuals. An additional comparison was performed between seronegative and chronic Chagas cardiomyopathy individuals. Differences between allele and genotype frequencies in individuals were determined using the χ 2 test and logistic regression analysis when necessary. The Benjamini and Hochberg step up FDR correction was used in all analyses. Odds ratios and 95% confidence intervals were calculated according to Woolf's method. The statistical software package Plink V1.07 (http://pngu.mgh.harvard.edu/purcell/plink) was used to perform all analyses. 39 A P-value of less than 0.05 was considered to be statistically significant. Pairwise linkage disequilibrium (D′ and r 2 ) and haplotypes were estimated using an expectation-maximization algorithm implemented in Haploview 4.2 software. 37 Statistical power of our study was calculated by using Power Calculator for Genetic Studies 2006 (CaTS) software (http://www.sph.umich.edu/csg/abecasis/CaTS/).
